



Black Hairy Tongue as a Side Effect of Immune Checkpoint Inhibition: A Case Report



Olivia Madalone, BS¹; Medha Venigalla, BS¹; Maximilian Hemmrich, MD²; Amanda Kacioglu, MD²

¹Pritzker School of Medicine, University of Chicago; ²Department of Surgery – ENT, University of Chicago

Background

Immune checkpoint inhibitors (ICIs), including PD-1 inhibitors like **pembrolizumab**, are widely used in melanoma, NSCLC, and HNSCC.

ICIs are associated with **immune-related adverse events** such as fatigue, rash, diarrhea, and endocrinopathies.


Oral side effects include xerostomia, gingival bleeding, oral ulcers, and stomatitis.

Black hairy tongue (BHT), or lingua villosa nigra, is a rare, benign condition caused by hypertrophy of the filiform papillae.

Only **one other case** of pembrolizumab-associated BHT has been reported.

Case Timeline

July 2022: Vaginal melanoma diagnosed




Oct 2022: Pembrolizumab started




Nov-Dec 2022: Completed pelvic radiation



June 2023: First noted BHT



Sept 2023: BHT recurrence with oral ulcers



Dec 2023: Pembrolizumab completed; partial improvement of BHT



June 2024: Significant resolution of BHT

Case Summary

82F with vaginal mucosal melanoma **on pembrolizumab**.

No risk factors for BHT (non-smoker, good hygiene, no antibiotics).

June 2023: PCP noted **black discoloration of tongue**, asymptomatic.

Improved with chlorhexidine rinses but recurred in Sept 2023 with **migrating ulcers and gingival bleeding** (Figure 1).

Dec 2023: **Pembrolizumab completed**; partial resolution (Figure 2).

June 2024: **Marked improvement** with supportive care alone (Figure 3).




Figure 1. Dorsal surface (left) and base (right) of tongue in Sept 2023.




Figure 2. Dorsal surface of tongue in Dec 2023.

Figure 3. Dorsal surface of tongue in June 2024.

Discussion

Black hairy tongue (BHT):

- Caused by hypertrophy and elongation of filiform papillae
- Associated with poor oral hygiene, smoking, xerostomia, and antibiotics
- Benign, self-limited, but may cause concern for malignancy in oncology patients

ICI-related BHT:

- Extremely rare; only 2nd reported case with pembrolizumab
- Likely mechanism: immune modulation altering oral flora and mucosal turnover
- In this case, BHT recurred but resolved gradually with supportive care (oral rinses, salt water) after ICI completion

Clinical relevance:

- Recognition prevents unnecessary workup or interventions
- Important for oncologists, otolaryngologists, and dentists to be aware of rare ICI oral side effects

Conclusions

Pembrolizumab, in rare cases, **can cause black hairy tongue** (BHT).

Only the **second reported case** in the literature.

Condition is **benign, self-resolving** with supportive care.

Awareness is essential for oncologists, ENT providers, and dental professionals **as ICI use expands**.

Multidisciplinary vigilance for both common and rare ICI side effects **improves patient care** and **reduces unnecessary interventions**.

Contact

Olivia Madalone and Medha Venigalla
Pritzker School of Medicine

omadalone@uchicagomedicine.org
medha01@uchicagomedicine.org

References

1. National Cancer Institute. Pembrolizumab. National Cancer Institute. Published August 3, 2022. Accessed August 30, 2024. <https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab>
2. Keytruda. Head and Neck Cancer. Keytruda. Published 2024. Accessed August 30, 2024. <https://www.keytruda.com/head-and-neck-cancer/>
3. Black CM, Hanna GI, Wang L, et al. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma [published correction appears in *Front Oncol*. 2023 Jul 17;13:1240947. *Front Oncol*. 2023;13:160144. Published 2023 May 22. doi:10.3389/fonc.2023.1160144]
4. de Souza LG, Ferrarotto R. Pembrolizumab in the first-line treatment of advanced head and neck cancer. *Expert Rev Anticancer Ther*. 2021;21(12):1321-1331. doi:10.1080/14737140.2021.1996228
5. Acar C, Sahn G, Yüksel HÇ, Karaca B. Rare immune-related adverse effect of pembrolizumab: pulmonary hypertension. *J Chemother*. Published online May 8, 2024. doi:10.1080/1120009X.2024.2349858
6. Gurvits GE, Tan A. Black hairy tongue syndrome. *World J Gastroenterol*. 2014;20(31):10845-10850. doi:10.3748/wjg.v20.i31.10845
7. Gandhi L, Rodriguez-Abreu D, Gadgil S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018;378(22):2078-2092. doi:10.1056/NEJMoa1801005
8. Cecchi C, Marinello A, Cariño S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature. *Clin Lung Cancer*. 2021;22(6):e804-e807. doi:10.1016/j.cllc.2021.03.008